Silk Road Medical Inc
Change company Symbol lookup
Select an option...
SILK Silk Road Medical Inc
HLVX Hillevax Inc
AIZ Assurant Inc
NOTV Inotiv Inc
MYD BlackRock MuniYield
WPC WP Carey Inc
ATCO-I Atlas Corp
ATLX Atlas Lithium Corp
SRRK Scholar Rock Holding Corp
SCLX Scilex Holding Co
Go

Health Care : Health Care Equipment & Supplies | Small Cap Blend
Company profile

Silk Road Medical, Inc. is a medical device company, which is focused on reducing the risk of stroke and its devastating impact. The Company has discovered an approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR), which relies on two concepts: minimally invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain and combines the benefits of innovative endovascular techniques with fundamental surgical principles. The Company's ENROUTE Transcarotid Neuroprotection System (NPS) and ENROUTE Transcarotid Stent System are the products for use in TCAR. Its ENROUTE Transcarotid Stent System is placed during a period of temporary high-rate blood flow reversal, which is enabled by its ENROUTE Transcarotid NPS. It markets and sells its products in the United States through a direct sales organization consisting of approximately 64 sales representatives and 62 clinical support specialists.

Closing Price
$55.57
Day's Change
1.21 (2.23%)
Bid
--
Ask
--
B/A Size
--
Day's High
55.90
Day's Low
54.00
Volume
(Below Average)
Volume:
264,483

10-day average volume:
306,620
264,483

DEADLINE ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 14, 2022 in Palantir Lawsuit - PLTR

12:35 pm ET November 13, 2022 (Newsfile) Print

New York, New York--(Newsfile Corp. - November 13, 2022) - Levi & Korsinsky, LLP notifies investors in Palantir Technologies Inc. ("Palantir" or the "Company") (NYSE: PLTR) of a class action securities lawsuit.

The lawsuit on behalf of Palantir investors has been commenced in the the United States District Court for the District of Colorado. This lawsuit is on behalf of all purchasers of Class A common stock during the period September 30, 2020 to August 5, 2022, including purchases pursuant and/or traceable to documents used in connection with the offer, sale, and direct listing of Palantir Class A common stock on the New York Stock Exchange beginning on or about September 30, 2020. Follow the link below to get more information and be contacted by a member of our team:

https://www.zlk.com/pslra-1/palantir-lawsuit-loss-submission-form?prid=33618&wire=5

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/7091/144018_444747_logo.jpg





Cannot view this video? Visit:

https://www.youtube.com/watch?v=ykLxGvtBhcY

Palantir Technologies Inc. NEWS - PLTR NEWS

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) Palantir's investments in marketable securities were having a significant negative impact on the Company's earnings per share ("EPS") results; (ii) Palantir overstated the sustainability of its government segment's growth and revenues; (iii) Palantir was experiencing a significant slowdown in revenue growth, particularly among its government customers, despite ongoing global conflicts and market disruptions; (iv) as a result of all the foregoing, the Company was likely to miss consensus estimates for its first quarter 2022 EPS and second quarter 2022 sales outlook; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

WHAT THIS MEANS TO SHAREHOLDERS: If you suffered a loss in Palantir during the relevant timeframe, you have until November 14, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. Discuss your rights with our legal team without cost or obligation.

PROTECT YOUR FINANCIAL INTERESTS: Complete this brief submission form https://www.zlk.com/pslra-1/palantir-lawsuit-loss-submission-form?prid=33618&wire=5 or call 212-363-7500 to discuss the case.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/144018

comtex tracking

COMTEX_418778229/2523/2022-11-13T12:35:05

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.